Protocol Ledger

NCT03717155 · Phase II · COMPLETED

Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC

Interventional Phase II clinical trial protocol NCT03717155 sponsored by EMD Serono / Merck KGaA in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-10-30 Enrollment: 43 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03717155
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)43 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03717155
Protocol FieldVerified Registry Value
NCT IdentifierNCT03717155
Consolidated Lead SponsorEMD Serono / Merck KGaA
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment43 participants (ACTUAL)
Registered Start Date2018-10-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03717155
Hospital Research SiteLocationSite Profile
Hospital Regional Universitario de MalagaMálaga, SpainOpen Hospital Dossier ->
Hospital Universitario Virgen del RocioSeville, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI